Risk factors for recurrent wheezing in preterm infants who received prophylaxis with palivizumab.
Mariana Bueno ManiniNatasha Yumi MatsunagaLívea GianfrancescoMarina Simões OliveiraMaria Rosa Vieira de CarvalhoGisleine Leila Martins Tengler RibeiroEliane de Oliveira MoraisMaria Ângela Gonçalves de Oliveira RibeiroAndré Moreno MorcilloJosé Dirceu RibeiroAdyleia Aparecida Dalbo Contrera ToroPublished in: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (2021)
Preterm infants who received prophylaxis with palivizumab but have a personal/family history of atopy or bronchopulmonary dysplasia are more likely to have RW than do those without these conditions.